Assessment of Side Effects of COVID-19 Vaccine Among General Population attending Kalar COVID-19 Vaccine Centers, Sulaimaniyah, Iraq

Authors

  • Baxan Farman Hama Amin Department of Nursing, Kalar Private Technical Institute, Sulaimani, Kurdistan Region, Iraq. Author
  • Omed Ahmed Muhammed College of Medicine, University of Garmyan, Sulaimani, Kurdistan Region, Iraq. Author

DOI:

https://doi.org/10.17656/jzs.10935

Keywords:

COVID-19, vaccination, side effects, sociodemographic factors, occupation, gender

Abstract

Background: The SARS-CoV-2 virus is an extraordinary virus that has become a severe public health problem; the symptoms that usually end in mortality include fever, dry cough, tiredness, shortness of breath, chills and etc.

 

Objectives: This study examines the potential relationship between sociodemographic factors and the side effects of COVID-19 vaccination.

 

Patients and Methods: A total of 511 participants were included in this study and were distributed according to their sociodemographic characteristics, including gender, age, marital status, education level, and occupation. Data on vaccination side effects were collected at 24 hours, 72 hours, and one week after vaccination. Statistical analysis was performed to identify significant associations between sociodemographic factors and vaccination side effects.

 

Results: most patients were aged between (40-65 years), females, married, housewives, illiterate, and lived in an urban area. The study's findings revealed insufficient awareness in >50% of patients. A highly significant correlation between awareness and the level of education has been founded and also a significant association with age, gender, and profession was found. At the same time, marital status and residency didn't affect the awareness.

 

Conclusions: This study highlights the importance of considering sociodemographic factors in assessing COVID-19 vaccine side effects. The findings show that occupation and gender may significantly predict vaccine side effects and should be considered when evaluating vaccine safety and efficacy.

References

Johansson, M. A., Quandelacy, T. M., Kada, S., Prasad, P. V., Steele, M., Brooks, J. T., ... & Butler, J. C.

(2021). SARS-CoV-2 transmission from people without COVID-19 symptoms. JAMA network open, 4(1),

e2035057-e2035057.

Kaur, S. P., & Gupta, V. (2020). COVID-19 Vaccine: A comprehensive status report. Virus Research, 288, DOI: https://doi.org/10.1016/j.virusres.2020.198114

The COVID-19 pandemic remains public health emergency of international concern. 2020.

https://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-COVID19/news/news/2020/5/COVID-19-pandemic-remains-public-health-emergency-of-international-concern

Pollard, A. J. (2020). Notice of supplement to an article reporting Oxford trial of ChAdOx1 nCoV-19 DOI: https://doi.org/10.1016/S0140-6736(20)32467-3

vaccine. The Lancet, 396(10263), e89.

Forni, G., & Mantovani, A. (2021). COVID-19 vaccines: where we stand and challenges ahead. Cell DOI: https://doi.org/10.1038/s41418-020-00720-9

Death & Differentiation, 28(2), 626-639.

Cao, M., Su, X., & Jiang, S. (2021). Broad-spectrum anti-coronavirus vaccines and therapeutics to combat

the current COVID-19 pandemic and future coronavirus disease outbreaks. Stem Cell Reports, 16(3), 398- DOI: https://doi.org/10.1016/j.stemcr.2020.12.010

COVID-19 vaccine: Sarah Gilbert, the woman behind the Oxford coronavirus vaccine (The Times of India)

- https://timesofindia.indiatimes.com/life-style/health-fitness/health-news/coronavirus-vaccine-sarah-gilbertthe-woman-behind-the-oxford-coronavirus-vaccine/articleshow/77110192.cms

NIH clinical trial of an investigational vaccine for COVID-19 begins (National Institutes of Health) -

https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-COVID-19-begins

Pfizer-BioNTech vaccine - mRNA vaccine: https://www.cdc.gov/coronavirus/2019-

ncov/vaccines/different-vaccines/Pfizer-BioNTech.html

COVID-19 vaccines: The race to end the pandemic (European Medicines Agency) -

https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-diseaseCOVID-19/treatments-vaccines/COVID-19-vaccines-race-end-pandemic

Johnson and Johnson vaccine-Viral vector vaccine: https://www.cdc.gov/coronavirus/2019-

ncov/vaccines/different-vaccines/janssen.html

Moderna vaccine - mRNA vaccine: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/differentvaccines/Moderna.html

AstraZeneca vaccine - Viral vector vaccine: https://www.who.int/news-room/feature-stories/detail/theoxford-astrazeneca-COVID-19-vaccine-what-you-need-to-know

Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., ... & Gruber, W. C.

(2020). Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. New England Journal of Medicine,

(27), 2603-2615.

Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., ... & Bijker, E.

(2021). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim

analysis of four randomized controlled trials in Brazil, South Africa, and the UK. The Lancet, 397(10269),

-111.

Jabal, K. A., Ben-Amram, H., Beiruti, K., Batheesh, Y., Sussan, C., Zarka, S., & Edelstein, M. (2021).

Impact of age, gender, ethnicity and prior disease status on immunogenicity following administration of a

single dose of the BNT162b2 mRNA COVID-19 Vaccine: real-world evidence from Israeli healthcare

workers, December-January 2020. medRxiv, 2021-01.

Blumenthal, K. G., Freeman, E. E., Saff, R. R., Robinson, L. B., Wolfson, A. R., Foreman, R. K., ... &

Shenoy, E. S. (2021). Delayed significant local reactions to mRNA-1273 vaccine against SARS-CoV-2. New DOI: https://doi.org/10.1056/NEJMc2102131

England Journal of Medicine, 384(13), 1273-1277.

Published

2023-12-20

How to Cite

Assessment of Side Effects of COVID-19 Vaccine Among General Population attending Kalar COVID-19 Vaccine Centers, Sulaimaniyah, Iraq. (2023). Journal of Zankoy Sulaimani - Part A, 25(2), 14. https://doi.org/10.17656/jzs.10935